@xconomy.com 2 months ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com 4 months ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com 7 months ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 8 months ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 8 months ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 1 year ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com 2 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?